Colon Polyps, Hereditary Syndromes, and Colorectal/Anal Cancer – Comprehensive Study Notes

Types of Colorectal Polyps

  • Non-neoplastic (generally benign)
    • Hamartomatous polyps
    • Juvenile polyps
    • Hyperplastic mucosal proliferation
    • Hyperplastic polyp → most common finding on routine colonoscopy; histology often reported simply as “hyperplastic.”
  • Neoplastic / Premalignant
    • Adenomatous polyp (tubular, villous, or tubulovillous sub-types)
    • Principal precursor for >90\% of colorectal adenocarcinomas.
    • Sessile serrated adenoma/polyp (SSP) and traditional serrated adenomas (TSAs).

Clinical Manifestations of Polyps

  • Usually asymptomatic.
  • Symptomatic when large (typically >10\,\text{mm}) or numerous:
    • Intermittent painless rectal bleeding (occult or overt)
    • Diarrhea or constipation
    • Change in caliber → "pencil-thin" stools
    • Obstructive symptoms if very large or clustered
  • Always ask about: frequency, color, shape; encourage photos (common with smartphones).

Diagnostic Work-up for Polyps

  • Gold standard → Colonoscopy (visualization + immediate polypectomy/biopsy).
  • Ancillary / adjunctive tests:
    • Fecal occult blood test (FOBT) or FIT
    • Limitation: not all polyps bleed → false negatives possible.
    • Flexible sigmoidoscopy (only distal colon viewed).
    • Capsule endoscopy (swallowed camera).
    • Stool DNA testing (e.g., Cologuard®)
    • Dual target: mutated DNA fragments and occult blood.
    • CT colonography ("virtual colonoscopy").

Treatment & Surveillance of Polyps

  • Polypectomy during colonoscopy = first-line therapy.
  • Multiple polyps (e.g., familial syndromes) → subtotal or total colectomy may be required.
  • Follow-up colonoscopy intervals (average guidance):
    • Hyperplastic polyps only → repeat in 10 yr10\,\text{yr}.
    • 1–2 small (<10 mm) tubular adenomas → 5–10 yr5–10\,\text{yr}.
    • ≥3 adenomas, any adenoma ≥10 mm, villous features, HGD, or serrated lesions → 3 yr3\,\text{yr} or sooner per risk factors.

Hereditary Polyposis & Cancer Syndromes

  • Familial Adenomatous Polyposis (FAP)
    • Autosomal dominant mutation in APC gene.
    • Hundreds–thousands of adenomas; ≈100%\approx100\% risk of colorectal cancer by age 40.
    • Management: genetic testing, annual colonoscopy in childhood, proctocolectomy with ileal pouch–anal anastomosis (IPAA) or ileostomy; EGD q1–3 yr for duodenal polyps.
  • Hamartomatous Polyposis Syndromes (e.g., Peutz-Jeghers)
    • Autosomal dominant; mucocutaneous hyperpigmented macules (lips, perioral skin).
    • GI + extra-GI malignancy risk; begin screening at age 12.
  • Serrated Polyposis Syndrome (SPS)
    • ≥5 serrated lesions proximal to sigmoid with ≥2 >10 mm OR ≥20 serrated lesions total with any ≥5 proximal to rectum.
    • Requires intensive colonoscopic surveillance (often annually).

Small-Bowel Neoplasms (Brief)

  • Malignant: adenocarcinoma, carcinoid (neuroendocrine), sarcoma, lymphoma.
  • Benign: adenoma, leiomyoma, lipoma.
  • Rare; often present as small-bowel obstruction.

Colorectal Cancer (CRC)

Epidemiology

  • 2nd leading cause of U.S. cancer death.
  • ≈90%\approx90\% are adenocarcinomas; most common sites = rectum & sigmoid.

Etiology & Risk Factors

  • Family history: 1º relative → 2×2\times risk; dx <45 yr → 4×4\times risk.
  • Genetic syndromes: FAP (100 % risk), HNPCC/Lynch (≈40 % risk), SPS.
  • Diet: high red/processed meat, animal fat, high-fructose corn syrup, “ultra-processed” foods.
  • Lifestyle: smoking, obesity, alcohol, DM, physical inactivity.
  • Chronic inflammation: IBD (UC > Crohn’s).

Natural History / Adenoma–Carcinoma Sequence

  • Initiation (mutation) → promotion (adenoma) over 10–20 yr10–20\,\text{yr} → progression to carcinoma → metastasis (0–5 yr).

Clinical Presentation

  • Early: asymptomatic, vague fatigue/weight loss.
  • Later: hematochezia/melena, change in bowel habits, obstruction/perforation, pencil stools.
  • Metastatic signs: hepatomegaly, ascites, back pain (bone mets).

Diagnostics

  • Colonoscopy + biopsy = gold standard.
  • Labs: CBC (microcytic anemia), CMP; CEA baseline (prognosis/surveillance).
    • α\alpha-Fetoprotein ↑ in rare aggressive CRC – bad prognosis.
  • Imaging: CT chest/abdomen/pelvis ± MRI for staging; PET if needed.

Staging (AJCC TNM)

  • Stage I–II (localized) → surgery alone often curative.
  • Stage III (node +) → surgery + adjuvant chemo.
  • Stage IV (metastatic) → systemic chemo ± targeted biologics ± palliative surgery.

Treatment Overview

  • Colon: Segmental colectomy with regional lymphadenectomy ± chemo.
  • Rectum: Multimodality—chemoradiation, total mesorectal excision; sphincter-preservation vs APR considered individually.

Prognosis

  • 5-yr overall survival ≈65%65\%.
    • Localized >90\% vs distant disease ≈15%\approx15\%.

Post-Treatment Surveillance

  • H&P + CEA q3–6 mo × 2 yr, then q6 mo to 5 yr.
  • CT CAP annually × 3 yr.
  • Colonoscopy at 1 yr post-op, then q3–5 yr.

Screening Recommendations (USPSTF & GI societies)

Average-Risk Individuals

  • Begin at age 45.
  • Preferred: Colonoscopy q10 yr.
  • Acceptable alternatives:
    • Flexible sigmoidoscopy q5 yr (q10 yr if combined with annual FIT).
    • CT colonography q5 yr.
    • Stool tests:
    • Annual FIT
    • High-sensitivity guaiac FOBT (Hemoccult Sensa®) annually
    • Multitarget DNA + FIT (Cologuard®) q1–3 yr.

Family History Modifications

  • 1º relative dx ≥60 yr → start age 40; colonoscopy q10 yr.
  • 1º relative dx <60 yr OR ≥2 1º relatives any age → start age 40 or 10 yr before earliest diagnosis (whichever first); colonoscopy q5 yr.

Case Study – “Philip” (Mucinous Adenocarcinoma)

  • Male, metabolic syndrome from adolescence, poor diet (“zero fruits/vegetables”).
  • At 22 yr developed rectal bleeding → colonoscopy: mucinous adenocarcinoma removed endoscopically; tattoo placed.
  • Surgeon deferred resection (“nothing seen”).
  • 1 yr later: severe abdominal pain → MRI: diffuse skeletal & peritoneal mets.
  • Died age 27.
    → Illustrates aggressiveness of mucinous subtype, importance of definitive resection & vigilant follow-up, and lifestyle contributions.

Anal Cancer

  • Most = Squamous cell carcinoma strongly linked to HPV (types 16/18).
    • Rising incidence with receptive anal intercourse & in HIV-positive pts.
  • Symptoms: rectal bleeding, pain, pruritus, mass/ulcer misdiagnosed as hemorrhoid.
  • Work-up: DRE, anoscopy with biopsy, HPV/STI tests, CT/MRI/PET for staging.
  • Tx: chemoradiation (Nigro protocol) ± excision; APR reserved for refractory disease → lifelong colostomy.
  • Surveillance: DRE + inguinal nodes q3–6 mo × 5 yr; CT CAP annually × 3 yr.
  • Women with anal cancer → heightened risk for cervical cancer → ensure Pap/HPV screening.

HPV Vaccination Guidance

  • Routine: start age 11–12 yr (can begin at 9 yr).
  • Catch-up permissible through age 26; ≥27 yr requires shared decision-making (off-label but safe; consider if minimal prior exposure).
  • Vaccine prevents future infection; does NOT treat existing HPV.

Lifestyle & Dietary Counseling (Prevention & Adjunct Therapy)

  • Emphasize whole foods “without labels”: fresh fruits, vegetables, lean meats, fish.
  • Limit red/processed meats, sugary beverages, ultra-processed foods.
  • Encourage regular physical activity; weight control.
  • Smoking cessation & moderation/avoidance of alcohol.
  • Manage comorbid DM, HTN, dyslipidemia aggressively.

Practical Pearls for the PA / Primary-Care Provider

  • Hyperplastic polyps (few) → reassure, 10-yr scope; BUT ≥5 hyperplastic, especially proximal or clustered in rectum → consider SPS & shorten interval.
  • Document screening discussions & chosen modality.
  • Elevated pre-op CEA or failure to normalize post-op → search for occult mets.
  • Unexplained iron-deficiency anemia in adults warrants colonoscopy—even in absence of overt GI symptoms.
  • Non-healing perianal lesion ≠ "just hemorrhoids" → biopsy!